View source for Warfarin

{{Short description|Anticoagulant medication}}
{{Redirect|Coumadin|the class of compounds known as "coumadins"|Coumadins|the natural compound|Coumarin}}
{{Redirect|Waran|the Polish Armored Personnel Carrier|Waran (armored personnel carrier)}}
{{Good article}}
{{Use dmy dates|date=January 2024}}
{{Use American English|date=June 2018}}
{{cs1 config|name-list-style=vanc|display-authors=6}}
{{Infobox drug
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 460939157
| image = Warfarin.svg
| image_class = skin-invert-image
| width = 200
| alt = 
| image2 = Warfarin ball-and-stick model from xtal 2002.png
| width2 = 250
| alt2 = 
| caption =
<!-- Clinical data -->
| pronounce = {{IPAc-en|ˈ|w|ɔːr|f|ər|ɪ|n}}
| tradename = Coumadin, others<ref name=brands /><ref name=brands2/><ref name=brands3/>
| Drugs.com = {{drugs.com|monograph|warfarin-sodium}}
| MedlinePlus = a682277
| DailyMedID = Warfarin
| pregnancy_AU = D
| pregnancy_AU_comment = <ref name="Drugs.com pregnancy">{{cite web | title=Warfarin Use During Pregnancy | website=Drugs.com | date=4 September 2019 | url=https://www.drugs.com/pregnancy/warfarin.html | access-date=7 February 2020 | archive-date=9 February 2018 | archive-url=https://web.archive.org/web/20180209025743/https://www.drugs.com/pregnancy/warfarin.html | url-status=live }}</ref>
| pregnancy_category =
| routes_of_administration = [[Oral administration|By mouth]], [[intravenous therapy|intravenous]]
| class = 
| ATC_prefix = B01
| ATC_suffix = AA03
| ATC_supplemental = {{ATCvet|B01|AA03}}

<!-- Legal status -->
| legal_AU = S4
| legal_AU_comment = 
| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F -->
| legal_BR_comment = 
| legal_CA = Rx-only
| legal_CA_comment = <ref>{{cite web | title=Product information | website=[[Health Canada]] | date=3 August 2000 | url=https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=163 | access-date=23 September 2024 | archive-date=23 September 2024 | archive-url=https://web.archive.org/web/20240923050123/https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=163 | url-status=live }}</ref><ref>{{cite web | title=Product information | website=[[Health Canada]] | date=30 June 2020 | url=https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12818 | access-date=23 September 2024 | archive-date=23 September 2024 | archive-url=https://web.archive.org/web/20240923050024/https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12818 | url-status=live }}</ref>
| legal_DE = <!-- Anlage I, II, III or Unscheduled -->
| legal_DE_comment = 
| legal_NZ = <!-- Class A, B, C -->
| legal_NZ_comment = 
| legal_UK = POM
| legal_UK_comment = <ref>{{cite web | title=Summary of Product Characteristics (SmPC) | website=(emc) | date=7 November 2023 | url=https://www.medicines.org.uk/emc/product/2803/smpc | access-date=23 September 2024 | archive-date=18 August 2022 | archive-url=https://web.archive.org/web/20220818112658/https://www.medicines.org.uk/emc/product/2803/smpc | url-status=live }}</ref>
| legal_US = Rx-only
| legal_US_comment = <ref name="Coumadin FDA label">{{cite web | title=Coumadin- warfarin sodium tablet | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ebcb71e-9a7e-4969-abb9-7c7d3e3aae3c | access-date=25 December 2021 | archive-date=26 December 2021 | archive-url=https://web.archive.org/web/20211226074624/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ebcb71e-9a7e-4969-abb9-7c7d3e3aae3c | url-status=live }}</ref>
| legal_EU = 
| legal_EU_comment = 
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV -->
| legal_UN_comment = 
| legal_status = <!-- For countries not listed above -->

<!-- Pharmacokinetic data -->
| bioavailability = 79–100% (by mouth)<ref name = PCK>{{cite journal | vauthors = Holford NH | title = Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship | journal = Clinical Pharmacokinetics | volume = 11 | issue = 6 | pages = 483–504 | date = December 1986 | pmid = 3542339 | doi = 10.2165/00003088-198611060-00005 | s2cid = 92210077 }}</ref>
| protein_bound = 99%<ref name=TGA/>
| metabolism = [[Liver]]: [[CYP2C9]], [[CYP2C19|2C19]], 2C8, 2C18, [[CYP1A2|1A2]] and [[CYP3A4|3A4]]<ref name = TGA />
| metabolites = 
| onset = 
| elimination_half-life = 7 days (active half-life is 20-60 hours)<ref name = TGA />
| duration_of_action = 
| excretion = [[Kidney]] (92%)<ref name = TGA />

<!-- Identifiers -->
| index2_label = as salt
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 81-81-2
| CAS_number2 = 129-06-6
| CAS_supplemental = 
| PubChem = 54678486
| PubChem2 = 16204922
| IUPHAR_ligand = 6853
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB00682
| DrugBank2 = DBSALT000278
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 10442445
| ChemSpiderID2 = 17333193
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 5Q7ZVV76EI
| UNII2 = 6153CWM0CL
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08682
| KEGG2 = D00564
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 10033
| ChEBI2 = 10034
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1464
| ChEMBL2 = 1200879
| NIAID_ChemDB = 
| PDB_ligand = RWF
| PDB_ligand2 = SWF<!-- this is broken; PDB is R,S enantiomer but that won't fit into chembox -->
| synonyms =

<!-- Chemical and physical data -->
| IUPAC_name = (''RS'')-4-Hydroxy-3-(3-oxo-1-phenylbutyl)- 2''H''-chromen-2-one
| C = 19
| H = 16
| O = 4
| SMILES = CC(=O)CC(C\1=C(/O)c2ccccc2OC/1=O)c3ccccc3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,21H,11H2,1H3
| StdInChI_comment = 
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = PJVWKTKQMONHTI-UHFFFAOYSA-N
| density = 
| density_notes = 
| melting_point = 
| melting_high = 
| melting_notes = 
| boiling_point = 
| boiling_notes = 
| solubility = 
| sol_units = 
| specific_rotation = 
}}

<!-- Definition and medical uses -->
'''Warfarin''', sold under the brand name '''Coumadin''' among others, is used as an [[anticoagulant|anticoagulant medication]].<ref name="AHFS2017" /><ref name="Coumadin FDA label" /> It is commonly used to prevent [[deep vein thrombosis]] and [[pulmonary embolism]], and to protect against [[stroke]] in people who have [[atrial fibrillation]], [[valvular heart disease]], or [[artificial heart valves]].<ref name="AHFS2017" /> Warfarin may sometimes be prescribed following a [[ST-segment elevation myocardial infarction]] and [[orthopedic surgery]].<ref name="AHFS2017" /> It is usually taken by mouth, but may also be administered [[intravenous]]ly.<ref name="AHFS2017">{{cite web |title = Warfarin sodium |url = https://www.drugs.com/monograph/warfarin-sodium.html |publisher = The American Society of Health-System Pharmacists |date = 13 October 2022 |access-date = 16 February 2023 |archive-date = 12 June 2018 |archive-url = https://web.archive.org/web/20180612143838/https://www.drugs.com/monograph/warfarin-sodium.html |url-status = live }}</ref>

<!-- Side effects -->
The common [[side effect]], a natural consequence of reduced clotting, is [[bleeding]].<ref name=AHFS2017 /> Less common side effects may include areas of [[tissue necrosis|tissue damage]], and [[purple toes syndrome]].<ref name=AHFS2017 /> Use is not recommended during [[pregnancy]].<ref name=AHFS2017 /> The effects of warfarin are typically monitored by checking [[prothrombin time]] (INR) every one to four weeks.<ref name=AHFS2017 /> Many other medications and [[Diet (nutrition)|dietary factors]] can interact with warfarin, either increasing or decreasing its effectiveness.<ref name=AHFS2017 /><ref name=Ag2012>{{cite journal | vauthors = Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G | title = Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | journal = Chest | volume = 141 | issue = 2 Suppl | pages = e44S–e88S | date = February 2012 | pmid = 22315269 | pmc = 3278051 | doi = 10.1378/chest.11-2292 }}</ref> The effects of warfarin may be reversed with [[phytomenadione]] (vitamin K<sub>1</sub>), [[fresh frozen plasma]], or [[prothrombin complex concentrate]].<ref name=Ag2012 />

<!-- Mechanism -->
Warfarin decreases blood clotting by blocking [[vitamin K epoxide reductase]], an [[enzyme]] that reactivates [[vitamin K1|vitamin K<sub>1</sub>]].<ref name=Ag2012 /> Without sufficient active vitamin K<sub>1</sub>, the plasma concentrations of [[clotting factors]] II, VII, IX, and X are reduced and thus have decreased clotting ability.<ref name=Ag2012 /> The anticlotting [[protein C]] and [[protein S]] are also inhibited, but to a lesser degree.<ref name=Ag2012 /> 
It is wrongly described as a "vitamin K antagonist". This term is incorrect. Warfarin does not antagonize the action of vitamin K1, but rather antagonizes vitamin K1 recycling, depleting active vitamin K1.
A few days are required for full effect to occur, and these effects can last for up to five days.<ref name=AHFS2017 /><ref>{{cite book | vauthors = Arcangelo VP, Peterson AM |title = Pharmacotherapeutics for Advanced Practice: A Practical Approach |date = 2006 |publisher = Lippincott Williams & Wilkins |isbn = 978-0-7817-5784-3 |page = 774 |url = https://books.google.com/books?id=EaP1yJz4fkEC&pg=PA774 |url-status = live |archive-url = https://web.archive.org/web/20170918185711/https://books.google.com/books?id=EaP1yJz4fkEC&pg=PA774 |archive-date = 18 September 2017 }}</ref> Because the mechanism involves enzymes such as ''[[VKORC1]]'', patients on warfarin with [[Genetic polymorphism|polymorphisms of the enzymes]] may require adjustments in therapy if the genetic variant that they have is more readily inhibited by warfarin, thus requiring lower doses.<ref>{{cite book | vauthors = Dasgupta A, Wahed A | chapter = Pharmacogenomics | title = Clinical Chemistry, Immunology and Laboratory Quality Control |date=2014 |pages=353–362 |doi=10.1016/B978-0-12-407821-5.00020-6| isbn = 978-0-12-407821-5 }}</ref>

<!-- History and culture -->
Warfarin first came into large-scale commercial use in 1948 as a [[rat poison]].<ref>{{cite book | vauthors = Ravina E |title = The Evolution of Drug Discovery: From Traditional Medicines to Modern Drugs |date = 2011 |publisher = John Wiley & Sons |isbn = 978-3-527-32669-3 |page = 148 |url = https://books.google.com/books?id=iDNy0XxGqT8C&pg=PA148 |url-status = live |archive-url = https://web.archive.org/web/20170918185711/https://books.google.com/books?id=iDNy0XxGqT8C&pg=PA148 |archive-date = 18 September 2017 }}</ref><ref name=poison/> It was formally approved as a medication to treat blood clots in humans by the U.S. [[Food and Drug Administration]] in 1954.<ref name=AHFS2017 /> In 1955, warfarin's reputation as a safe and acceptable treatment for [[coronary artery disease]], [[arterial plaques]], and [[ischemic strokes]] was bolstered when President [[Dwight D. Eisenhower]] was treated with warfarin following a highly publicized heart attack.<ref>{{cite journal | vauthors = Lim GB | title = Milestone 2: Warfarin: from rat poison to clinical use | journal = Nature Reviews. Cardiology | date = December 2017 | pmid = 29238065 | doi = 10.1038/nrcardio.2017.172 | doi-access = free | title-link=doi }}</ref> It is on the [[WHO Model List of Essential Medicines|World Health Organization's List of Essential Medicines]].<ref name="WHO23rd">{{cite book | vauthors = ((World Health Organization)) | title = The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023) | year = 2023 | hdl = 10665/371090 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MHP/HPS/EML/2023.02 | hdl-access=free }}</ref> Warfarin is available as a [[generic medication]]<ref name=BNF69>{{cite book |title = British national formulary |date = 2015 |publisher = British Medical Association |isbn = 978-0-85711-156-2 |pages = 154–155 |edition = 69 }}</ref> and is sold under many brand names.<ref name=brands/> In 2023, it was the 116th most commonly prescribed medication in the United States, with more than 5{{nbsp}}million prescriptions.<ref name="Top300Drugs">{{cite web | title=Top 300 of 2023 | url=https://clincalc.com/DrugStats/Top300Drugs.aspx | website=ClinCalc | access-date=12 August 2025 | archive-date=12 August 2025 | archive-url=https://web.archive.org/web/20250812130026/https://clincalc.com/DrugStats/Top300Drugs.aspx | url-status=live }}</ref><ref>{{cite web | title = Warfarin Drug Usage Statistics, United States, 2013 - 2023 | website = ClinCalc | url = https://clincalc.com/DrugStats/Drugs/Warfarin | access-date = 18 August 2025}}</ref>
{{TOC limit}}

== Medical uses ==
Warfarin is [[indicated]] for the prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism;<ref name="Coumadin FDA label" /> prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement;<ref name="Coumadin FDA label" /> and reduction in the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.<ref name="Coumadin FDA label" />

Warfarin is used to decrease the tendency for [[thrombosis]], or as secondary [[prophylaxis]] (prevention of further episodes) in those individuals who have already formed a blood clot ([[thrombus]]). Warfarin treatment can help prevent formation of future blood clots and help reduce the risk of [[embolism]] (migration of a thrombus to a spot where it blocks [[blood supply]] to a [[vital organ]]).<ref name=AHFS>{{cite web |title = Coumadin |url = https://www.drugs.com/monograph/coumadin.html |publisher = The American Society of Health-System Pharmacists |access-date = 3 April 2011 |url-status = live |archive-url = https://web.archive.org/web/20110203081242/http://www.drugs.com/monograph/coumadin.html |archive-date = 3 February 2011 }}</ref><ref>{{cite book | vauthors = Sanders GD, Lowenstern A, Borre E, Chatterjee R, Goode A, Sharan L, Lapointe NA, Raitz G, Shah B, Yapa R, Davis JK |title=Stroke Prevention in Patients With Atrial Fibrillation: A Systematic Review Update |series=AHRQ Comparative Effectiveness Reviews |date=2018 |publisher=Agency for Healthcare Research and Quality (US) |url=https://www.ncbi.nlm.nih.gov/books/NBK534141/ |pmid=30480925 }}</ref>

Warfarin is best suited for anticoagulation (clot formation inhibition) in areas of slowly running blood (such as in veins and the pooled blood behind artificial and natural valves), and in blood pooled in dysfunctional [[atrium (heart)|cardiac atria]]. Thus, common clinical indications for warfarin use are [[atrial fibrillation]], the presence of [[artificial heart valve]]s, [[deep venous thrombosis]], and [[pulmonary embolism]] (where the embolized clots first form in veins). Warfarin is also used in [[antiphospholipid syndrome]]. It has been used occasionally after heart attacks ([[myocardial infarction]]s), but is far less effective at preventing new thromboses in [[coronary arteries]]. Prevention of clotting in arteries is usually undertaken with [[antiplatelet drug]]s, which act by a different mechanism from warfarin (which normally has no effect on platelet function).<ref name="Hirsh_2003">{{cite journal | vauthors = Hirsh J, Fuster V, Ansell J, Halperin JL | title = American Heart Association/American College of Cardiology Foundation guide to warfarin therapy | journal = Journal of the American College of Cardiology | volume = 41 | issue = 9 | pages = 1633–1652 | date = May 2003 | pmid = 12742309 | doi = 10.1016/S0735-1097(03)00416-9 | author-link2 = Valentín Fuster | doi-access = free | title-link=doi | author-link4 = Jonathan L. Halperin }}</ref> It can be used to treat people following [[ischemic stroke]]s due to [[atrial fibrillation]], though [[direct oral anticoagulant]]s (DOACs) may offer greater benefits.<ref>{{cite journal | vauthors = Kim IS, Kim HJ, Kim TH, Uhm JS, Joung B, Lee MH, Pak HN | title = Appropriate doses of non-vitamin K antagonist oral anticoagulants in high-risk subgroups with atrial fibrillation: Systematic review and meta-analysis | journal = Journal of Cardiology | volume = 72 | issue = 4 | pages = 284–291 | date = October 2018 | pmid = 29706404 | doi = 10.1016/j.jjcc.2018.03.009 | doi-access = free | title-link=doi }}</ref>

=== Dosing ===
Dosing of warfarin is complicated because it is known to interact with many commonly used medications and [[Vitamin K#Food sources|certain foods]].<ref name=Holbrook2005>{{cite journal | vauthors = Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS | title = Systematic overview of warfarin and its drug and food interactions | journal = Archives of Internal Medicine | volume = 165 | issue = 10 | pages = 1095–1106 | date = May 2005 | pmid = 15911722 | doi = 10.1001/archinte.165.10.1095 | doi-access =  | title-link=doi }}</ref> These interactions may enhance or reduce warfarin's anticoagulation effect. To optimize the therapeutic effect without risking dangerous [[side effect]]s such as bleeding, close monitoring of the degree of anticoagulation is required by a [[blood test]] measuring an [[prothrombin time]] (INR). During the initial stage of treatment, INR is checked daily; intervals between tests can be lengthened if the patient manages stable therapeutic INR levels on an unchanged warfarin dose.<ref name="Hirsh_2003" /> Newer [[point-of-care testing]] is available and has increased the ease of INR testing in the outpatient setting. Instead of a [[blood draw]], the point-of-care test involves a simple finger prick.<ref name="Perry 2010">{{cite journal | vauthors = Perry DJ, Fitzmaurice DA, Kitchen S, Mackie IJ, Mallett S | title = Point-of-care testing in haemostasis | journal = British Journal of Haematology | volume = 150 | issue = 5 | pages = 501–514 | date = September 2010 | pmid = 20618331 | doi = 10.1111/j.1365-2141.2010.08223.x | s2cid = 32069018 | doi-access = free }}</ref>

==== Maintenance dose ====
[[File:Vitamin K1 warfarin therapeutic window.png|thumb|[[Vitamin K1]]-warfarin interaction effect: When warfarin levels are high, people have more risk of bleeding. Conversely, lower levels of warfarin lead to increased risk of blood clots. A narrow range exists where the benefits of warfarin are greater than the risks, its [[therapeutic window]]. Certain drugs, herbal medicines, and foods can interact with warfarin, increasing or decreasing a previously stable warfarin level.<ref>{{cite web | work = U.S. National Institutes of Health |title = important information to know when you are taking: Coumadine and vitamine K |url = http://ods.od.nih.gov/pubs/factsheets/coumadin1.pdf |access-date = 27 March 2014 |archive-url = https://web.archive.org/web/20131020203725/http://ods.od.nih.gov/pubs/factsheets/coumadin1.pdf |archive-date = 20 October 2013 }}</ref>]]
Recommendations by many national bodies, including the [[American College of Chest Physicians]],<ref name=Holbrook2012>{{cite journal | vauthors = Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH | title = Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | journal = Chest | volume = 141 | issue = 2 Suppl | pages = e152S–e184S | date = February 2012 | pmid = 22315259 | pmc = 3278055 | doi = 10.1378/chest.11-2295 }}</ref> have been distilled to help manage dose adjustments.<ref name="pmid15926414">{{cite journal | vauthors = Ebell MH | title = Evidence-based adjustment of warfarin (Coumadin) doses | journal = American Family Physician | volume = 71 | issue = 10 | pages = 1979–1982 | date = May 2005 | pmid = 15926414 | url = https://www.aafp.org/afp/2005/0515/p1979.html | url-status = live | archive-url = https://web.archive.org/web/20180201075216/https://www.aafp.org/afp/2005/0515/p1979.html | archive-date = 1 February 2018 }}</ref>

The [[maintenance dose]] of warfarin can fluctuate significantly depending on the amount of vitamin K<sub>1</sub> in the diet. Keeping vitamin K<sub>1</sub> intake at a stable level can prevent these fluctuations. [[Leafy green vegetable]]s tend to contain higher amounts of vitamin K<sub>1</sub>. Green parts of members of the family [[Apiaceae]], such as [[parsley]], [[cilantro]], and [[dill]] are extremely rich sources of vitamin K; [[cruciferous vegetables]] such as [[cabbage]] and [[broccoli]], as well as the darker varieties of [[lettuce]]s and other [[leafy green]]s, are also relatively high in vitamin K<sub>1</sub>. Green vegetables such as [[peas]] and [[green beans]] do not have such high amounts of vitamin K<sub>1</sub> as leafy greens. Certain [[vegetable oil]]s have high amounts of vitamin K<sub>1</sub>. Foods low in vitamin K<sub>1</sub> include roots, bulbs, tubers, and most fruits and fruit juices. Cereals, grains, and other milled products are also low in vitamin K<sub>1</sub>.<ref>{{cite web |url = https://www.mayoclinic.org/diseases-conditions/thrombophlebitis/expert-answers/warfarin/faq-20058443 |title = Warfarin diet: What foods should I avoid? |publisher = Mayo Foundation |access-date = 9 August 2011 |url-status = live |archive-url = https://web.archive.org/web/20110824075323/http://www.mayoclinic.com/health/warfarin/AN00455 |archive-date = 24 August 2011 }}</ref> 

Several studies reported that the maintenance dose can be predicted based on various clinical data.<ref>{{cite journal | vauthors = Hu YH, Wu F, Lo CL, Tai CT | title = Predicting warfarin dosage from clinical data: a supervised learning approach | journal = Artificial Intelligence in Medicine | volume = 56 | issue = 1 | pages = 27–34 | date = September 2012 | pmid = 22537823 | doi = 10.1016/j.artmed.2012.04.001 }}</ref><ref>{{cite journal | vauthors = Solomon I, Maharshak N, Chechik G, Leibovici L, Lubetsky A, Halkin H, Ezra D, Ash N | title = Applying an artificial neural network to warfarin maintenance dose prediction | journal = The Israel Medical Association Journal | volume = 6 | issue = 12 | pages = 732–735 | date = December 2004 | pmid = 15609884 }}</ref>

==== Self-testing ====
{{Main|INR self-monitoring}}
[[File:INR self test.jpg|thumb|INR self-monitoring with one blood drop. The INR is too high and the warfarine dose must be decreased.]]
Anticoagulation with warfarin can also be monitored by patients at home. International guidelines on home testing were published in 2005.<ref name="Ansell2005">{{cite journal | vauthors = Ansell J, Jacobson A, Levy J, Völler H, Hasenkam JM | title = Guidelines for implementation of patient self-testing and patient self-management of oral anticoagulation. International consensus guidelines prepared by International Self-Monitoring Association for Oral Anticoagulation | journal = International Journal of Cardiology | volume = 99 | issue = 1 | pages = 37–45 | date = March 2005 | pmid = 15721497 | doi = 10.1016/j.ijcard.2003.11.008 | url = http://patientselftesting.com/uploads/Int_Cardio_Journal_-_Patient_Self_Management.pdf | archive-url = https://web.archive.org/web/20160303221536/http://patientselftesting.com/uploads/Int_Cardio_Journal_-_Patient_Self_Management.pdf | archive-date = 3 March 2016 }}</ref> The guidelines stated:<ref name="Ansell2005" />

{{blockquote|The consensus agrees that patient self-testing and patient self-management are effective methods of monitoring oral anticoagulation therapy, providing outcomes at least as good as, and possibly better than, those achieved with an anticoagulation clinic. All patients must be appropriately selected and trained. Currently available self-testing/self-management devices give INR results that are comparable with those obtained in laboratory testing.}}

A 2006 [[systematic review]] and [[meta-analysis]] of 14 [[randomized trial]]s showed home testing led to a reduced incidence of complications ([[thrombosis]] and [[Bleeding|major bleeding]]), and improved the time in the [[Therapeutic index|therapeutic range]].<ref>{{cite journal | vauthors = Heneghan C, Alonso-Coello P, Garcia-Alamino JM, Perera R, Meats E, Glasziou P | title = Self-monitoring of oral anticoagulation: a systematic review and meta-analysis | journal = Lancet | volume = 367 | issue = 9508 | pages = 404–411 | date = February 2006 | pmid = 16458764 | doi = 10.1016/S0140-6736(06)68139-7 | url = http://www.hadassah.org.il/NR/rdonlyres/7DD940DC-E6B5-43FA-8869-288CAE8FF831/7797/Selfmonitoringoforalanticoagulationasystematicrevi.pdf | s2cid = 1494933 | archive-url = https://web.archive.org/web/20120319160502/http://www.hadassah.org.il/NR/rdonlyres/7DD940DC-E6B5-43FA-8869-288CAE8FF831/7797/Selfmonitoringoforalanticoagulationasystematicrevi.pdf | archive-date = 19 March 2012 }}</ref>

=== Alternative anticoagulants ===
In some countries, other [[coumarin]]s are used instead of warfarin, such as [[acenocoumarol]] and [[phenprocoumon]]. These have a shorter (acenocoumarol) or longer (phenprocoumon) [[Biological half-life|half-life]], and are not completely interchangeable with warfarin. Several types of anticoagulant drugs offering the efficacy of warfarin without a need for monitoring, such as [[dabigatran]], [[apixaban]], [[edoxaban]], and [[rivaroxaban]], have been approved in a number of countries for classical warfarin uses. Complementing these drugs are [[reversal agent]]s available for dabigatran ([[idarucizumab]]), and for apixaban, and rivaroxaban ([[andexanet alfa]]).<ref>{{cite journal | vauthors = Cuker A, Burnett A, Triller D, Crowther M, Ansell J, Van Cott EM, Wirth D, Kaatz S | title = Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum | journal = American Journal of Hematology | volume = 94 | issue = 6 | pages = 697–709 | date = June 2019 | pmid = 30916798 | doi = 10.1002/ajh.25475 | doi-access = free | title-link=doi }}</ref> Andexanet alfa is suggested for edoxaban, but use of it is considered off label due to limited evidence. A reversal agent for dabigatran, apixaban, edoxaban, and rivaroxaban is in development ([[ciraparantag]]).<ref>{{cite journal | vauthors = Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz JI | title = When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH | journal = Journal of Thrombosis and Haemostasis | volume = 14 | issue = 3 | pages = 623–627 | date = March 2016 | pmid = 26911798 | doi = 10.1111/jth.13227 | doi-access =  | title-link=doi | s2cid = 27269191 }}</ref><!-- An initial failure was [[ximelagatran]] (trade name Exanta), however, reports of [[hepatotoxicity]] (liver damage) prompted its manufacturer to withdraw it from further development. A similar and later drug dabigatran has since been more successful -->

== Contraindications ==
All anticoagulants are generally contraindicated in situations in which the reduction in clotting that they cause might lead to serious and potentially life-threatening bleeds. This includes people with active bleeding conditions (such as [[gastrointestinal ulcer]]s), or disease states with increased risk of bleeding (e.g., low platelets, severe liver disease, uncontrolled hypertension). For patients undergoing surgery, treatment with anticoagulants is generally suspended. Similarly, spinal and [[lumbar puncture]] (e.g., spinal injections, [[epidural]]s, etc.) carry increased risk, so treatment is suspended prior to these procedures.<ref name="martindale">Brayfield A (ed), Martindale: The Complete Drug Reference [online] London: Pharmaceutical Press [accessed on 24 April 2017]</ref><ref name=FDA2015>{{cite web |title = Coumadin |url = https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/009218s115lbl.pdf |website = U.S. [[Food and Drug Administration]] (FDA) |access-date = 24 April 2017 |date = October 2015 |archive-url = https://web.archive.org/web/20170623024610/https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/009218s115lbl.pdf |archive-date = 23 June 2017 }}</ref>

Warfarin should not be given to people with [[heparin-induced thrombocytopenia]] until [[platelet count]] has improved or normalised.<ref name="martindale" /> Warfarin is usually best avoided in people with protein C or protein S deficiency, as these [[thrombophilia|thrombophilic]] conditions increase the risk of skin [[necrosis]], which is a rare but serious side effect associated with warfarin.<ref name="rapini">{{cite book | vauthors = Bolognia JL, Jorizzo JL, Rapini RP |title = Dermatology |url = https://archive.org/details/dermatologyvolum00mdje |url-access = limited |date = 2008 |publisher = Mosby/Elsevier |location = St. Louis, Mo. |isbn = 978-1-4160-2999-1 |pages = [https://archive.org/details/dermatologyvolum00mdje/page/n350 331], 340 |edition = 2nd }}</ref>

=== Pregnancy ===
{{further|Fetal warfarin syndrome|Anticoagulation in pregnancy}}
Warfarin is [[contraindication|contraindicated]] in pregnancy, as it passes through the [[placenta]]l barrier and may cause bleeding in the fetus; warfarin use during pregnancy is commonly associated with [[miscarriage|spontaneous abortion]], [[stillbirth]], [[perinatal mortality#Neonatal mortality|neonatal death]], and [[preterm birth]].<ref name=HDT>{{cite book |vauthors = Macina OT, Schardein JL |title = Human Developmental Toxicants |publisher = CRC Taylor & Francis |chapter = Warfarin |location = Boca Raton |year = 2007 |pages = 193–4 |isbn = 978-0-8493-7229-2 |chapter-url = https://books.google.com/books?id=8_Lc58cGZj0C |access-date = 26 August 2020 |archive-date = 5 March 2024 |archive-url = https://web.archive.org/web/20240305112952/https://books.google.com/books?id=8_Lc58cGZj0C |url-status = live }} Retrieved on 15 December 2008 through [[Google Book Search]].</ref> Coumarins (such as warfarin) are also [[teratogen]]s, that is, they cause [[birth defect]]s; the incidence of birth defects in infants exposed to warfarin ''[[Uterus|in utero]]'' appears to be around 5%, although higher figures (up to 30%) have been reported in some studies.<ref name=Loftus>{{cite book |vauthors = Loftus CM |title = Neurosurgical Aspects of Pregnancy |chapter = Fetal toxicity of common neurosurgical drugs |publisher = American Association of Neurological Surgeons |location = Park Ridge, Ill |year = 1995 |pages = 11–3 |isbn = 978-1-879284-36-4 |chapter-url = https://books.google.com/books?id=X58R5BqtHmEC |access-date = 26 August 2020 |archive-date = 5 March 2024 |archive-url = https://web.archive.org/web/20240305112942/https://books.google.com/books?id=X58R5BqtHmEC |url-status = live }}</ref> Depending on when exposure occurs during pregnancy, two distinct combinations of [[congenital]] abnormalities can arise.<ref name=HDT />

==== First trimester of pregnancy ====
Usually, warfarin is avoided in the [[first trimester]], and a [[low-molecular-weight heparin]] such as [[enoxaparin]] is substituted. With heparin, risks of [[maternal haemorrhage]] and other complications are still increased, but heparins do not cross the placental barrier, so do not cause birth defects.<ref name=Loftus /> Various solutions exist for the time around delivery.

When warfarin (or another 4-hydroxycoumarin derivative) is given during the first trimester—particularly between the sixth and ninth weeks of pregnancy—a constellation of birth defects known variously as [[fetal warfarin syndrome]] (FWS), warfarin embryopathy, or coumarin embryopathy can occur. FWS is characterized mainly by [[skeletal]] abnormalities, which include nasal [[hypoplasia]], a depressed or narrowed [[nasal bridge]], [[scoliosis]], and [[calcification]]s in the [[vertebral column]], [[femur]], and [[calcaneus|heel bone]], which show a peculiar [[stipple]]d appearance on [[medical radiography|X-rays]]. [[Dysmelia|Limb abnormalities]], such as [[brachydactyly]] (unusually short fingers and toes) or underdeveloped extremities, can also occur.<ref name=HDT /><ref name=Loftus /> Common nonskeletal features of FWS include [[low birth weight]] and [[developmental disability|developmental disabilities]].<ref name=HDT /><ref name=Loftus />

==== Second trimester and later ====
Warfarin administration in the second and third trimesters is much less commonly associated with birth defects, and when they do occur, are considerably different from FWS. The most common congenital abnormalities associated with warfarin use in late pregnancy are [[central nervous system]] disorders, including [[spasticity]] and [[seizure]]s, and eye defects.<ref name=HDT /><ref name=Loftus /> Because of such later pregnancy birth defects, anticoagulation with warfarin poses a problem in pregnant women requiring warfarin for vital indications, such as stroke prevention in those with artificial heart valves.

Warfarin may be used in [[lactating]] women who wish to breastfeed their infants.<ref name="Bates 2012">{{cite journal | vauthors = Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO | title = VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | journal = Chest | volume = 141 | issue = 2 Suppl | pages = e691S–e736S | date = February 2012 | pmid = 22315276 | pmc = 3278054 | doi = 10.1378/chest.11-2300 }}</ref> Available data does not suggest that warfarin crosses into the breast milk. Similarly, INR levels should be checked to avoid adverse effects.<ref name="Bates 2012" />

== Adverse effects ==

=== Bleeding ===
The only common side effect of warfarin is hemorrhage. The risk of severe bleeding is small but definite (a typical yearly rate of 1–3% has been reported),<ref name=Holbrook2012 /> and any benefit needs to outweigh this risk when warfarin is considered. All types of bleeding occur more commonly, but the most severe ones are those involving the brain ([[intracerebral hemorrhage]]/[[hemorrhagic stroke]]) and the [[spinal cord]].<ref name=Holbrook2012 /> Risk of bleeding is increased if the INR is out of range (due to accidental or deliberate overdose or due to interactions).<ref name=Garcia2010>{{cite journal | vauthors = Garcia D, Crowther MA, Ageno W | title = Practical management of coagulopathy associated with warfarin | journal = BMJ | volume = 340 | article-number = c1813 | date = April 2010 | pmid = 20404060 | doi = 10.1136/bmj.c1813 | s2cid = 37076001 }}</ref> This risk increases greatly once the INR exceeds 4.5.<ref name=Brown2015>{{cite journal | vauthors = Brown DG, Wilkerson EC, Love WE | title = A review of traditional and novel oral anticoagulant and antiplatelet therapy for dermatologists and dermatologic surgeons | journal = Journal of the American Academy of Dermatology | volume = 72 | issue = 3 | pages = 524–534 | date = March 2015 | pmid = 25486915 | doi = 10.1016/j.jaad.2014.10.027 }}</ref>

Several risk scores exist to predict bleeding in people using warfarin and similar anticoagulants. A commonly used score ([[HAS-BLED]]) includes known predictors of warfarin-related bleeding: uncontrolled high [[blood pressure]] (H), abnormal [[renal function|kidney function]] (A), previous stroke (S), known previous bleeding condition (B), previous [[labile]] INR when on anticoagulation (L), elderly as defined by age over 65 (E), and drugs associated with bleeding (e.g., aspirin) or alcohol misuse (D). While their use is recommended in clinical practice guidelines,<ref name=Camm2012>{{cite journal | vauthors = Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P | title = 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association | journal = European Heart Journal | volume = 33 | issue = 21 | pages = 2719–2747 | date = November 2012 | pmid = 22922413 | doi = 10.1093/eurheartj/ehs253 | doi-access = free | title-link = doi | url = https://boris.unibe.ch/15016/1/ehs253.pdf | access-date = 5 March 2024 | archive-date = 27 January 2024 | archive-url = https://web.archive.org/web/20240127015717/https://boris.unibe.ch/15016/1/ehs253.pdf | url-status = live }}</ref> they are only moderately effective in predicting bleeding risk and do not perform well in predicting hemorrhagic stroke.<ref>{{cite journal | vauthors = Shoeb M, Fang MC | title = Assessing bleeding risk in patients taking anticoagulants | journal = Journal of Thrombosis and Thrombolysis | volume = 35 | issue = 3 | pages = 312–319 | date = April 2013 | pmid = 23479259 | pmc = 3888359 | doi = 10.1007/s11239-013-0899-7 }}</ref> Bleeding risk may be increased in people on [[hemodialysis]].<ref name="pmid17720522">{{cite journal | vauthors = Elliott MJ, Zimmerman D, Holden RM | title = Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates | journal = American Journal of Kidney Diseases | volume = 50 | issue = 3 | pages = 433–440 | date = September 2007 | pmid = 17720522 | doi = 10.1053/j.ajkd.2007.06.017 }}</ref> Another score used to assess bleeding risk on anticoagulation, specifically Warfarin or Coumadin, is the ATRIA score, which uses a weighted additive scale of clinical findings to determine bleeding risk stratification.<ref>{{cite journal | vauthors = Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE | title = A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study | journal = Journal of the American College of Cardiology | volume = 58 | issue = 4 | pages = 395–401 | date = July 2011 | pmid = 21757117 | pmc = 3175766 | doi = 10.1016/j.jacc.2011.03.031 }}</ref> The risks of bleeding are increased further when warfarin is combined with [[antiplatelet drug]]s such as [[clopidogrel]], [[aspirin]], or [[nonsteroidal anti-inflammatory drug]]s.<ref name="pmid17698822">{{cite journal | vauthors = Delaney JA, Opatrny L, Brophy JM, Suissa S | title = Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding | journal = CMAJ | volume = 177 | issue = 4 | pages = 347–351 | date = August 2007 | pmid = 17698822 | pmc = 1942107 | doi = 10.1503/cmaj.070186 }}</ref>

=== Warfarin necrosis ===
{{Main|Warfarin necrosis}}
A rare but serious complication resulting from treatment with warfarin is [[warfarin necrosis]], which occurs more frequently shortly after commencing treatment in patients with a deficiency of [[protein C]], an innate anticoagulant that, like the procoagulant factors whose synthesis warfarin inhibits, requires vitamin K-dependent [[carboxylation]] for its activity. Since warfarin initially decreases protein C levels faster than the coagulation factors, it can paradoxically increase the blood's tendency to coagulate when treatment is first begun (many patients when starting on warfarin are given [[heparin]] in parallel to combat this), leading to massive thrombosis with skin [[necrosis]] and [[gangrene]] of limbs. Its natural counterpart, [[purpura fulminans]], occurs in children who are [[homozygous]] for certain protein C mutations.<ref name="pmid10718793">{{cite journal | vauthors = Chan YC, Valenti D, Mansfield AO, Stansby G | title = Warfarin induced skin necrosis | journal = The British Journal of Surgery | volume = 87 | issue = 3 | pages = 266–272 | date = March 2000 | pmid = 10718793 | pmc = 4928566 | doi = 10.1046/j.1365-2168.2000.01352.x }}</ref>

=== Osteoporosis ===
After initial reports that warfarin could reduce [[bone mineral density]], several studies demonstrated a link between warfarin use and [[osteoporosis]]-related [[bone fracture|fracture]]. A 1999 study in 572 women taking warfarin for [[Deep vein thrombosis|deep venous thrombosis]], risk of [[Vertebral compression fracture|vertebral fracture]] and [[rib fracture]] was increased; other fracture types did not occur more commonly.<ref name="pmid10448778">{{cite journal | vauthors = Caraballo PJ, Heit JA, Atkinson EJ, Silverstein MD, O'Fallon WM, Castro MR, Melton LJ | title = Long-term use of oral anticoagulants and the risk of fracture | journal = Archives of Internal Medicine | volume = 159 | issue = 15 | pages = 1750–1756 | year = 1999 | pmid = 10448778 | doi = 10.1001/archinte.159.15.1750 | doi-access =  | title-link=doi }}</ref> A 2002 study looking at a randomly selected selection of 1,523 patients with [[osteoporotic]] fracture found no increased exposure to anticoagulants compared to controls, and neither did stratification of the duration of anticoagulation reveal a trend towards fracture.<ref>{{cite journal | vauthors = Pilon D, Castilloux AM, Dorais M, LeLorier J | title = Oral anticoagulants and the risk of osteoporotic fractures among elderly | journal = Pharmacoepidemiology and Drug Safety | volume = 13 | issue = 5 | pages = 289–294 | date = May 2004 | pmid = 15133779 | doi = 10.1002/pds.888 | s2cid = 45496277 }}</ref>

A 2006 retrospective study of 14,564 [[Medicare (United States)|Medicare]] recipients showed that warfarin use for more than one year was linked with a 60% increased risk of [[osteoporosis]]-related fracture in men, but no association in women was seen. The mechanism was thought to be a combination of reduced intake of vitamin K (a vitamin necessary for bone health) and inhibition by warfarin of vitamin K-mediated carboxylation of certain bone proteins, rendering them nonfunctional.<ref>{{cite journal | vauthors = Gage BF, Birman-Deych E, Radford MJ, Nilasena DS, Binder EF | title = Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2 | journal = Archives of Internal Medicine | volume = 166 | issue = 2 | pages = 241–246 | date = January 2006 | pmid = 16432096 | doi = 10.1001/archinte.166.2.241 | doi-access =  | title-link=doi }}</ref>

=== Purple toe syndrome ===
{{see also|Blue toe syndrome}}
Another rare complication that may occur early during warfarin treatment (usually within 3 to 8 weeks of commencement) is [[cholesterol embolism|purple toe syndrome]]. This condition is thought to result from small deposits of [[cholesterol]] breaking loose and causing embolisms in blood vessels in the skin of the feet, which causes a blueish-purple colour and may be painful.<ref>{{cite journal | vauthors = O'Keeffe ST, Woods BO, Breslin DJ, Tsapatsaris NP | title = Blue toe syndrome. Causes and management | journal = Archives of Internal Medicine | volume = 152 | issue = 11 | pages = 2197–2202 | date = November 1992 | pmid = 1444678 | doi = 10.1001/archinte.1992.00400230023004 }}</ref>

It is typically thought to affect the [[big toe]], but it affects other parts of the feet, as well, including the bottom of the foot ([[plantar]] surface). The occurrence of purple toe syndrome may require discontinuation of warfarin.<ref>{{cite journal | vauthors = Talmadge DB, Spyropoulos AC | title = Purple toes syndrome associated with warfarin therapy in a patient with antiphospholipid syndrome | journal = Pharmacotherapy | volume = 23 | issue = 5 | pages = 674–677 | date = May 2003 | pmid = 12741443 | doi = 10.1592/phco.23.5.674.32200 | s2cid = 28632135 }}</ref>

=== Calcification ===
Several studies have also implicated warfarin use in valvular and vascular [[calcification]]. No specific treatment is available, but some modalities are under investigation.<ref>{{cite journal | vauthors = Palaniswamy C, Sekhri A, Aronow WS, Kalra A, Peterson SJ | title = Association of warfarin use with valvular and vascular calcification: a review | journal = Clinical Cardiology | volume = 34 | issue = 2 | pages = 74–81 | date = February 2011 | pmid = 21298649 | pmc = 6652734 | doi = 10.1002/clc.20865 }}</ref>

== Overdose <span class="anchor" id="Reversal"></span>==
The major side effect of warfarin use is bleeding. Risk of bleeding is increased if the INR is out of range (due to accidental or deliberate overdose or due to interactions).<ref name=Garcia2010 /> Many drug interactions can increase the effect of warfarin, also causing an overdose.<ref name=Holbrook2005 />

In patients with supratherapeutic INR but INR less than 10 and no bleeding, it is enough to lower the dose or omit a dose, monitor the INR and resume warfarin at an adjusted lower dose when the target INR is reached.<ref name=Farinde2019>{{cite journal|url=https://emedicine.medscape.com/article/2172018-overview|title=Warfarin Overanticoagulation|website=Medscape|date=18 April 2019|author=Abimbola Farinde|access-date=19 August 2022|archive-date=19 August 2022|archive-url=https://web.archive.org/web/20220819155343/https://emedicine.medscape.com/article/2172018-overview|url-status=live}}</ref> For people who need rapid reversal of warfarin – such as due to serious bleeding – or who need emergency surgery, the effects of warfarin can be reversed with vitamin K, [[prothrombin complex concentrate]] (PCC), or [[fresh frozen plasma]] (FFP).<ref name=Ag2012 /> Generally, four-factor PCC can be given more quickly than FFP, the amount needed is a smaller volume of fluid than FFP, and does not require ABO [[blood typing]]. Administration of PCCs results in rapid hemostasis, similar to that of FFP, namely, with comparable rates of thromboembolic events, but with reduced rates of volume overload. Blood products should not be routinely used to reverse warfarin overdose, when vitamin K could work alone.<ref name=Ag2012 /> While PCC has been found in lab tests to be better than FFP, when rapid reversal is needed,<ref name=Chai2016>{{cite journal | vauthors = Chai-Adisaksopha C, Hillis C, Siegal DM, Movilla R, Heddle N, Iorio A, Crowther M | title = Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis | journal = Thrombosis and Haemostasis | volume = 116 | issue = 5 | pages = 879–890 | date = October 2016 | pmid = 27488143 | doi = 10.1160/TH16-04-0266 | s2cid = 4733615 }}</ref> as of 2018, whether a difference in outcomes such as death or disability exists is unclear.<ref>{{cite journal | vauthors = Tornkvist M, Smith JG, Labaf A | title = Current evidence of oral anticoagulant reversal: A systematic review | journal = Thrombosis Research | volume = 162 | pages = 22–31 | date = February 2018 | pmid = 29258056 | doi = 10.1016/j.thromres.2017.12.003 }}</ref>

When warfarin is being given and INR is in therapeutic range, simple discontinuation of the drug for five days is usually enough to reverse the effect and cause INR to drop below 1.5.<ref name="pmid12186515">{{cite journal | vauthors = Crowther MA, Douketis JD, Schnurr T, Steidl L, Mera V, Ultori C, Venco A, Ageno W | title = Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial | journal = Annals of Internal Medicine | volume = 137 | issue = 4 | pages = 251–254 | date = August 2002 | pmid = 12186515 | doi = 10.7326/0003-4819-137-4-200208200-00009 | s2cid = 10450603 }}</ref>

{|class=wikitable
|+Warfarin overdose recommendations<ref name=Farinde2019/>
|-
! Supratherapeutic INR but INR < 4.5, no bleeding
| 
*Lowering the dose or omit a dose
*Monitoring daily
*Resuming at an adjusted lower dose when the target INR is reached.
|-
! INR 4.5-10, no bleeding
|
*Omitting 1-2 doses
*Monitoring INR
*Readjusting dose
|-
! INR >10.0, no bleeding
|
*Holding warfarin, monitoring INR, and readjusting dose
*Vitamin K1 (phytonadione) 2-2.5&nbsp;mg PO or 0.5–1&nbsp;mg IV
|-
! Minor bleeding, any elevated INR:
| 
*Holding warfarin, monitoring INR, and readjusting dose
*Considering vitamin K1 (phytonadione) 2.5–5&nbsp;mg PO once, and may repeat if needed after 24 h
|-
! Major bleeding, any elevated INR
|
*Holding warfarin, monitoring INR, and readjusting dose
*Prothrombin complex concentrate plus vitamin K1 (phytonadione) 5–10&nbsp;mg IV
May also consider supplementation with fresh frozen plasma (FFP) or recombinant factor VIIa
|-
! Life-threatening bleeding and elevated INR:
|
*Holding warfarin therapy
*[[Fresh frozen plasma]] and vitamin K 10&nbsp;mg by slow IV infusion
|}

== Interactions ==

Warfarin [[drug interaction|interacts]] with many commonly used drugs, and the [[drug metabolism|metabolism]] of warfarin varies greatly between patients.<ref name=Holbrook2005 /> Some foods have also been reported to interact with warfarin.<ref name=Holbrook2005 /> Apart from the metabolic interactions, highly protein bound drugs can displace warfarin from [[serum albumin]] and cause an increase in the INR.<ref>{{cite journal | vauthors = Gage BF, Fihn SD, White RH | title = Management and dosing of warfarin therapy | journal = The American Journal of Medicine | volume = 109 | issue = 6 | pages = 481–488 | date = October 2000 | pmid = 11042238 | doi = 10.1016/S0002-9343(00)00545-3 }}</ref> This makes finding the correct dosage difficult, and accentuates the need of monitoring; when initiating a medication that is known to interact with warfarin (e.g., [[simvastatin]]), [[international normalized ratio|INR]] checks are increased or dosages adjusted until a new ideal dosage is found.

When taken with [[nonsteroidal anti-inflammatory drug]]s (NSAIDs), warfarin increases the risk for [[gastrointestinal bleeding]]. This increased risk is due to the antiplatelet effect of NSAIDs and possible damage to the gastrointestinal [[mucosa]].<ref>{{cite journal | vauthors = Ament PW, Bertolino JG, Liszewski JL | title = Clinically significant drug interactions | journal = American Family Physician | volume = 61 | issue = 6 | pages = 1745–1754 | date = March 2000 | pmid = 10750880 | url = https://www.aafp.org/pubs/afp/issues/2000/0315/p1745.html | access-date = 22 August 2023 | url-status = live | archive-url = https://web.archive.org/web/20160507065339/http://www.aafp.org/afp/2000/0315/p1745.html | archive-date = 7 May 2016 }}</ref><ref>{{cite journal | vauthors = Carpenter M, Berry H, Pelletier AL | title = Clinically Relevant Drug-Drug Interactions in Primary Care | journal = American Family Physician | volume = 99 | issue = 9 | pages = 558–564 | date = May 2019 | pmid = 31038898 | url = https://www.aafp.org/pubs/afp/issues/2019/0501/p558.html | access-date = 22 August 2023 | archive-date = 23 August 2023 | archive-url = https://web.archive.org/web/20230823020207/https://www.aafp.org/pubs/afp/issues/2019/0501/p558.html | url-status = live }}</ref>

Many commonly used [[antibiotic]]s, such as [[metronidazole]] or the [[macrolide]]s, greatly increase the effect of warfarin by reducing the metabolism of warfarin in the body. Other [[broad-spectrum antibiotic]]s can reduce the amount of the normal [[gut flora|bacterial flora in the bowel]], which make significant quantities of vitamin K<sub>1</sub>, thus potentiating the effect of warfarin.<ref name=Juurlink>{{cite journal | vauthors = Juurlink DN | title = Drug interactions with warfarin: what clinicians need to know | journal = CMAJ | volume = 177 | issue = 4 | pages = 369–371 | date = August 2007 | pmid = 17698826 | pmc = 1942100 | doi = 10.1503/cmaj.070946 }}</ref> In addition, food that contains large quantities of vitamin K<sub>1</sub> will reduce the warfarin effect.<ref name=Holbrook2005 /><ref name=Holbrook2012 /> [[Thyroid]] activity also appears to influence warfarin dosing requirements;<ref name=Kurnik>{{cite journal | vauthors = Kurnik D, Loebstein R, Farfel Z, Ezra D, Halkin H, Olchovsky D | title = Complex drug-drug-disease interactions between amiodarone, warfarin, and the thyroid gland | journal = Medicine | volume = 83 | issue = 2 | pages = 107–113 | date = March 2004 | pmid = 15028964 | doi = 10.1097/01.md.0000123095.65294.34 | s2cid = 43173080 | doi-access = free }}</ref> [[hypothyroidism]] (decreased thyroid function) makes people less responsive to warfarin treatment,<ref>{{cite journal | vauthors = Stephens MA, Self TH, Lancaster D, Nash T | title = Hypothyroidism: effect on warfarin anticoagulation | journal = Southern Medical Journal | volume = 82 | issue = 12 | pages = 1585–1586 | date = December 1989 | pmid = 2595433 | doi = 10.1097/00007611-198912000-00035 }}</ref> while [[hyperthyroidism]] (overactive thyroid) boosts the anticoagulant effect.<ref>{{cite journal | vauthors = Chute JP, Ryan CP, Sladek G, Shakir KM | title = Exacerbation of warfarin-induced anticoagulation by hyperthyroidism | journal = Endocrine Practice | volume = 3 | issue = 2 | pages = 77–79 | year = 1997 | pmid = 15251480 | doi = 10.4158/EP.3.2.77 }}</ref> Several mechanisms have been proposed for this effect, including changes in the rate of breakdown of clotting factors and changes in the metabolism of warfarin.<ref name=Kurnik /><ref>{{cite journal | vauthors = Kellett HA, Sawers JS, Boulton FE, Cholerton S, Park BK, Toft AD | title = Problems of anticoagulation with warfarin in hyperthyroidism | journal = The Quarterly Journal of Medicine | volume = 58 | issue = 225 | pages = 43–51 | date = January 1986 | pmid = 3704105 }}</ref>

Excessive use of alcohol is also known to affect the metabolism of warfarin and can elevate the INR, and thus increase the risk of bleeding.<ref>{{cite journal | vauthors = Weathermon R, Crabb DW | title = Alcohol and medication interactions | journal = Alcohol Research & Health | volume = 23 | issue = 1 | pages = 40–54 | year = 1999 | pmid = 10890797 | pmc = 6761694 }}</ref> The U.S. [[Food and Drug Administration]] (FDA) product insert on warfarin states that alcohol should be avoided.<ref name=TGA >{{cite web |title = PRODUCT INFORMATION COUMADIN |work = TGA eBusiness Services |publisher = Aspen Pharma Pty Ltd |date = 19 January 2010 |access-date = 11 December 2013 |url = https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-02588-3 |format = PDF |url-status = live |archive-url = https://web.archive.org/web/20151017135417/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-02588-3 |archive-date = 17 October 2015 }}</ref> The [[Cleveland Clinic]] suggests that when taking warfarin one should not drink more than "one beer, 6 oz of wine, or one shot of alcohol per day".<ref>{{cite web|url=https://my.clevelandclinic.org/health/drugs/16182-warfarin-a-blood-thinning-drug-what-you-need-to-know-|title=Warfarin Anticoagulant Medication|access-date=30 June 2020|archive-date=1 July 2020|archive-url=https://web.archive.org/web/20200701125620/https://my.clevelandclinic.org/health/drugs/16182-warfarin-a-blood-thinning-drug-what-you-need-to-know-|url-status=live}}</ref>

Warfarin also interacts with many herbs and spices,<ref name="drug-herb">{{cite book | vauthors = Austin S, Batz F | veditors = Lininger SW |title = A-Z guide to drug-herb-vitamin interactions: how to improve your health and avoid problems when using common medications and natural supplements together |publisher = Prima Health |location = Roseville, Calif |year = 1999 |page = [https://archive.org/details/azguidetodrugher0000unse/page/224 224] |isbn = 978-0-7615-1599-9 |url-access = registration |url = https://archive.org/details/azguidetodrugher0000unse/page/224 }}</ref> some used in food (such as [[ginger]] and [[garlic]]) and others used purely for medicinal purposes (such as [[ginseng]] and ''[[Ginkgo biloba]]''). All may increase bleeding and bruising in people taking warfarin; similar effects have been reported with [[borage oil|borage]] ([[Borage|starflower]]) oil.<ref>{{cite journal | vauthors = Heck AM, DeWitt BA, Lukes AL | title = Potential interactions between alternative therapies and warfarin | journal = American Journal of Health-System Pharmacy | volume = 57 | issue = 13 | pages = 1221–1227; quiz 1228–1230 | date = July 2000 | pmid = 10902065 | doi = 10.1093/ajhp/57.13.1221 | doi-access = free }}</ref> [[St. John's wort]], sometimes recommended to help with mild to moderate depression, reduces the effectiveness of a given dose of warfarin; it [[enzyme induction and inhibition|induces]] the enzymes that break down warfarin in the body, causing a reduced anticoagulant effect.<ref>{{cite web |url = http://www.rpsgb.org.uk/pdfs/scifactsheetstjwort.pdf |title = Herb-medicine interactions: St John's Wort (Hypericum perforatum) Useful information for pharmacist |access-date = 14 January 2009 |vauthors = Barnes J, ((Working Group on Complementary Medicine)) |date = September 2002 |publisher = [[Royal Pharmaceutical Society of Great Britain]] |location = London |page = 5 |archive-url = https://web.archive.org/web/20060924184428/http://www.rpsgb.org.uk/pdfs/scifactsheetstjwort.pdf |archive-date = 24 September 2006 }}</ref>

Between 2003 and 2004, the UK [[Committee on Safety of Medicines]] received several reports of increased INR and risk of haemorrhage in people taking warfarin and [[cranberry juice]].<ref>{{cite web |url = https://news.bbc.co.uk/2/hi/health/3120206.stm |title = Cranberry juice clot drug warning |work = BBC News |date = 18 September 2003 |access-date = 18 May 2008 |url-status = live |archive-url = https://web.archive.org/web/20080209212613/http://news.bbc.co.uk/1/hi/health/3120206.stm |archive-date = 9 February 2008 }}</ref><ref name=Suvarna>{{cite journal | vauthors = Suvarna R, Pirmohamed M, Henderson L | title = Possible interaction between warfarin and cranberry juice | journal = BMJ | volume = 327 | issue = 7429 | page = 1454 | date = December 2003 | pmid = 14684645 | pmc = 300803 | doi = 10.1136/bmj.327.7429.1454 }}</ref><ref name=Aston>{{cite journal | vauthors = Aston JL, Lodolce AE, Shapiro NL | title = Interaction between warfarin and cranberry juice | journal = Pharmacotherapy | volume = 26 | issue = 9 | pages = 1314–1319 | date = September 2006 | pmid = 16945054 | doi = 10.1592/phco.26.9.1314 | s2cid = 28468365 }}[https://www.medscape.com/s/viewarticle/545631 Free full text with registration at Medscape] {{webarchive|url=https://web.archive.org/web/20101109014448/http://www.medscape.com/viewarticle/545631 |date=9 November 2010 }}</ref> Data establishing a causal relationship are still lacking, and a 2006 review found no cases of this interaction reported to the USFDA;<ref name=Aston /> nevertheless, several authors have recommended that both doctors and patients be made aware of its possibility.<ref name=Pham>{{cite journal | vauthors = Pham DQ, Pham AQ | title = Interaction potential between cranberry juice and warfarin | journal = American Journal of Health-System Pharmacy | volume = 64 | issue = 5 | pages = 490–494 | date = March 2007 | pmid = 17322161 | doi = 10.2146/ajhp060370 }}</ref> The mechanism behind the interaction is still unclear.<ref name=Aston />

== Chemistry ==
[[File:warfarin tautomers.svg|class=skin-invert-image|thumb|upright=1.36|Acyclic tautomer ''(left)'' and cyclic hemiketal tautomer ''(right)'']]
X-ray [[crystallographic]] studies of warfarin show that it exists in [[tautomer]]ic form, as the cyclic [[hemiketal]], which is formed from the 4-hydroxycoumarin and the [[ketone]] in the 3-position substituent.<ref>{{cite journal |journal = [[Acta Crystallographica Section B]] |year = 1975 |volume = 31 |issue = 4 |pages = 954–960 |title = The crystal and molecular structure and absolute configuration of (−)-(''S'')-warfarin | vauthors = Valente EJ, Trager, Jensen LH |doi = 10.1107/S056774087500427X |bibcode = 1975AcCrB..31..954V |url = http://pilotscholars.up.edu/cgi/viewcontent.cgi?article=1004&context=chm_facpubs |archive-url = https://web.archive.org/web/20151020103015/http://pilotscholars.up.edu/cgi/viewcontent.cgi?article=1004&context=chm_facpubs |archive-date = 20 October 2015 |url-access = subscription }}</ref> However, the existence of many 4-hydroxycoumadin anticoagulants (for example [[phenprocoumon]]) that possess no ketone group in the 3-substituent to form such a structure, suggests that the hemiketal must tautomerise to the 4-hydroxy form in order for warfarin to be active.<ref name="pmid17691835">{{cite journal | vauthors = Karlsson BC, Rosengren AM, Andersson PO, Nicholls IA | title = The spectrophysics of warfarin: implications for protein binding | journal = The Journal of Physical Chemistry B | volume = 111 | issue = 35 | pages = 10520–10528 | date = September 2007 | pmid = 17691835 | doi = 10.1021/jp072505i | author-link4 = Ian A. Nicholls }}</ref>

=== Stereochemistry ===
Warfarin contains a [[stereocenter]] and consists of two [[enantiomer]]s. This is a [[racemate]], i.e., a 1: 1 mixture of ('' R '') – and the ('' S '') – form:<ref name="Rote Liste">{{cite book |publisher = Rote Liste Service GmbH |title = Rote Liste 2017 – Arzneimittelverzeichnis für Deutschland (einschließlich EU-Zulassungen und bestimmter Medizinprodukte) |location = Frankfurt/Main |year = 2017 |isbn = 978-3-946057-10-9 |page = 226 }}</ref>

{| class="wikitable" style="text-align:center"
|- class="hintergrundfarbe6"
! colspan="2"| Enantiomers of warfarin
|-
| [[File:(R)-Warfarin Structural Formula V1.svg|class=skin-invert-image|200 px]]<br /><small> CAS Number: 5543-58-8</small>
| [[File:(S)-Warfarin Structural Formula V1.svg|class=skin-invert-image|200 px]]<br /><small> CAS Number: 5543-57-7</small>
|}

== Pharmacology ==
[[File:Warfarintablets5-3-1.jpg|thumb|3&nbsp;mg (blue), 5&nbsp;mg (pink) and 1&nbsp;mg (brown) warfarin tablets (UK colours)]]

=== Pharmacokinetics ===
<!-- S-Waran redirects here -->
Warfarin consists of a [[racemic]] mixture of two active [[enantiomer]]s—''R''- and ''S''- forms—each of which is cleared by different pathways. S-warfarin is two to five times more potent than the R-isomer in producing an anticoagulant response.<ref name="Hirsh_2003" /> Both the enantiomers of warfarin undergo CYP-mediated metabolism by many different CYPs to form 3',4',6,7,8 and 10-hydroxy warfarin metabolites, major being 7-OH warfarin formed from S-warfarin by CYP2C9 and 10-OH warfarin from R-warfarin by CYP3A4.<ref>{{cite journal | vauthors = Shaik AN, Grater R, Lulla M, Williams DA, Gan LL, Bohnert T, LeDuc BW | title = Comparison of enzyme kinetics of warfarin analyzed by LC-MS/MS QTrap and differential mobility spectrometry | journal = Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences | volume = 1008 | issue = 1 | pages = 164–173 | date = January 2016 | pmid = 26655108 | doi = 10.1016/j.jchromb.2015.11.036 }}</ref>

Warfarin is slower-acting than the common anticoagulant [[heparin]], though it has a number of advantages. Heparin must be given by injection, whereas warfarin is available orally. Warfarin has a long half-life and need only be given once a day. Heparin can also cause a prothrombotic condition, [[heparin-induced thrombocytopenia]] (an [[antibody]]-mediated decrease in [[platelet]] levels), which increases the risk for thrombosis. It takes several days for warfarin to reach the therapeutic effect, since the circulating coagulation factors are not affected by the drug (thrombin has a half-life time of days). Warfarin's long half-life means that it remains effective for several days after it is stopped. Furthermore, if given initially without additional anticoagulant cover, it can increase thrombosis risk (see below).

=== Mechanism of action ===
Warfarin is one of several drugs often referred to as a "blood thinner"; this is not technically correct, as these drugs reduce coagulation of blood, increasing the [[clotting time]], without affecting the [[viscosity]] ("thickness") as such of blood.<ref>{{cite book|url=https://books.google.com/books?id=UtA8BAAAQBAJ&pg=PA138|isbn=978-0-19-997624-9|title=X-Ray Vision: The Evolution of Medical Imaging and Its Human Significance|date=28 November 2012|publisher=Oxford University Press|access-date=20 March 2023|archive-date=30 June 2023|archive-url=https://web.archive.org/web/20230630155034/https://books.google.com/books?id=UtA8BAAAQBAJ&pg=PA138|url-status=live}}</ref>

Warfarin inhibits the vitamin K-dependent synthesis of biologically active forms of the [[clotting]] factors [[thrombin|II]], [[factor VII|VII]], [[factor IX|IX]] and [[factor X|X]], as well as the regulatory factors protein C, protein S, and [[protein Z]].<ref name="Ansell">{{cite journal | vauthors = Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G | title = Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) | journal = Chest | volume = 133 | issue = 6 Suppl | pages = 160S–198S | date = June 2008 | pmid = 18574265 | doi = 10.1378/chest.08-0670 | s2cid = 12305488 }}</ref><ref>{{cite journal | vauthors = Freedman MD | title = Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects | journal = Journal of Clinical Pharmacology | volume = 32 | issue = 3 | pages = 196–209 | date = March 1992 | pmid = 1564123 | doi = 10.1002/j.1552-4604.1992.tb03827.x | s2cid = 38963632 }}</ref> Other proteins not involved in blood clotting, such as [[osteocalcin]], or [[matrix gla protein|matrix Gla protein]], may also be affected.
The precursors of these factors require [[gamma]] carboxylation of their [[glutamic acid]] residues to allow the coagulation factors to bind to [[phospholipid]] surfaces inside blood vessels, on the vascular [[endothelium]]. The [[enzyme]] that carries out the carboxylation of glutamic acid is [[gamma-glutamyl carboxylase]]. The carboxylation reaction proceeds only if the carboxylase enzyme is able to convert a [[reduction (chemistry)|reduced]] form of vitamin K (vitamin K hydroquinone) to vitamin K [[epoxide]] at the same time. The vitamin K epoxide is, in turn, recycled back to vitamin K and vitamin K [[hydroquinone]] by another enzyme, the [[vitamin K epoxide reductase]] (''VKOR''). Warfarin inhibits ''VKOR''<ref name=Whitlon>{{cite journal | vauthors = Whitlon DS, Sadowski JA, Suttie JW | title = Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition | journal = Biochemistry | volume = 17 | issue = 8 | pages = 1371–1377 | date = April 1978 | pmid = 646989 | doi = 10.1021/bi00601a003 }}</ref> (specifically the VKORC1 subunit<ref>{{cite journal | vauthors = Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW | title = Identification of the gene for vitamin K epoxide reductase | journal = Nature | volume = 427 | issue = 6974 | pages = 541–544 | date = February 2004 | pmid = 14765195 | doi = 10.1038/nature02254 | s2cid = 4424554 | bibcode = 2004Natur.427..541L }}</ref><ref name="pmid14765194">{{cite journal | vauthors = Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hörtnagel K, Pelz HJ, Lappegard K, Seifried E, Scharrer I, Tuddenham EG, Müller CR, Strom TM, Oldenburg J | title = Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 | journal = Nature | volume = 427 | issue = 6974 | pages = 537–541 | date = February 2004 | pmid = 14765194 | doi = 10.1038/nature02214 | s2cid = 4424197 | bibcode = 2004Natur.427..537R }}</ref>), thereby diminishing available vitamin K and vitamin K hydroquinone in the tissues, which decreases the carboxylation activity of the glutamyl carboxylase. When this occurs, the coagulation factors are no longer carboxylated at certain [[glutamic acid]] residues, and are incapable of binding to the endothelial surface of blood vessels, and are thus biologically inactive. As the body's stores of previously produced active factors degrade (over several days) and are replaced by inactive factors, the anticoagulation effect becomes apparent. The coagulation factors are produced, but have decreased functionality due to undercarboxylation; they are collectively referred to as PIVKAs (proteins induced [by] vitamin K absence), and individual coagulation factors as PIVKA-''number'' (e.g., [[Des-gamma carboxyprothrombin|PIVKA-II]]).

When warfarin is newly started, it may ''promote'' clot formation temporarily, because the level of proteins C and S are also dependent on vitamin K activity. Warfarin causes decline in protein C levels in first 36 hours. In addition, reduced levels of protein S lead to a reduction in activity of protein C (for which it is the co-factor), so reduces degradation of factor Va and factor VIIIa. Although loading doses of warfarin over 5&nbsp;mg also produce a precipitous decline in factor VII, resulting in an initial prolongation of the INR, full antithrombotic effect does not take place until significant reduction in factor II occurs days later. The haemostasis system becomes temporarily biased towards thrombus formation, leading to a prothrombotic state. Thus, when warfarin is loaded rapidly at greater than 5&nbsp;mg per day, to co-administering [[heparin]], an anticoagulant that acts upon [[antithrombin]] and helps reduce the risk of thrombosis, is beneficial, with warfarin therapy for four to five days, to have the benefit of anticoagulation from heparin until the full effect of warfarin has been achieved.<ref>{{cite journal | vauthors = Litin SC, Gastineau DA | title = Current concepts in anticoagulant therapy | journal = Mayo Clinic Proceedings | volume = 70 | issue = 3 | pages = 266–272 | date = March 1995 | pmid = 7861815 | doi = 10.4065/70.3.266 | doi-access = free | title-link=doi }}</ref><ref>{{cite journal | vauthors = Wittkowsky AK | title = Why warfarin and heparin need to overlap when treating acute venous thromboembolism | journal = Disease-a-Month | volume = 51 | issue = 2–3 | pages = 112–115 | year = 2005 | pmid = 15900262 | doi = 10.1016/j.disamonth.2005.03.005 }}</ref>

=== Pharmacogenomics ===
Warfarin activity is determined partially by genetic factors. [[Polymorphism (biology)|Polymorphisms]] in two genes (''VKORC1'' and ''CYP2C9'') play a particularly large role in response to warfarin.

''[[VKORC1]]'' polymorphisms explain 30% of the dose variation between patients:<ref name="pmid15883587">{{cite journal | vauthors = Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, Eriksson N, Wallerman O, Melhus H, Wadelius C, Bentley D, Deloukas P | title = Common VKORC1 and GGCX polymorphisms associated with warfarin dose | journal = The Pharmacogenomics Journal | volume = 5 | issue = 4 | pages = 262–270 | year = 2005 | pmid = 15883587 | doi = 10.1038/sj.tpj.6500313 | doi-access =  | title-link=doi }}</ref> particular [[mutation]]s make VKORC1 less susceptible to suppression by warfarin.<ref name="pmid14765194" /> There are two main haplotypes that explain 25% of variation: low-dose haplotype group (A) and a high-dose haplotype group (B).<ref name="pmid15930419">{{cite journal | vauthors = Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE | title = Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose | journal = The New England Journal of Medicine | volume = 352 | issue = 22 | pages = 2285–2293 | date = June 2005 | pmid = 15930419 | doi = 10.1056/NEJMoa044503 | doi-access = free | title-link=doi }}</ref> ''VKORC1'' polymorphisms explain why African Americans are on average relatively resistant to warfarin (higher proportion of group B [[haplotype]]s), while Asian Americans are generally more sensitive (higher proportion of group A haplotypes).<ref name="pmid15930419" /> Group A ''VKORC1'' polymorphisms lead to a more rapid achievement of a therapeutic INR, but also a shorter time to reach an INR over 4, which is associated with bleeding.<ref name="pmid18322281">{{cite journal | vauthors = Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, Kim RB, Roden DM, Stein CM | title = Genetic determinants of response to warfarin during initial anticoagulation | journal = The New England Journal of Medicine | volume = 358 | issue = 10 | pages = 999–1008 | date = March 2008 | pmid = 18322281 | pmc = 3894627 | doi = 10.1056/NEJMoa0708078 | doi-access = free | title-link=doi }}</ref>

''[[CYP2C9]]'' polymorphisms explain 10% of the dose variation between patients,<ref name="pmid15883587" /> mainly among [[Caucasian race|Caucasian]] patients as these variants are rare in African American and most Asian populations.<ref name="pmid15714076">{{cite journal | vauthors = Sanderson S, Emery J, Higgins J | title = CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis | journal = Genetics in Medicine | volume = 7 | issue = 2 | pages = 97–104 | date = February 2005 | pmid = 15714076 | doi = 10.1097/01.GIM.0000153664.65759.CF | doi-access =  | title-link=doi }}</ref> These ''CYP2C9'' polymorphisms do not influence time to effective INR as opposed to ''VKORC1'', but do shorten the time to [[International normalized ratio|INR]] > 4.<ref name="pmid18322281" />

Despite the promise of [[pharmacogenomic]] testing in warfarin dosing, its use in clinical practice is controversial. In August 2009, the [[Centers for Medicare and Medicaid Services]] concluded, "the available evidence does not demonstrate that pharmacogenomic testing of ''CYP2C9'' or ''VKORC1'' [[allele]]s to predict warfarin responsiveness improves health outcomes in [[Medicare (United States)|Medicare]] beneficiaries."<ref>{{cite web |url = https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=224&ver=15 <!-- http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=224&ver=15&NcaName=Pharmacogenomic+Testing+for+Warfarin+Response&NCDId=333&ncdver=1&IsPopup=y&bc=AAAAAAAAEAAA& --> |title = Decision Memo for Pharmacogenomic Testing for Warfarin Response (CAG-00400N) |vauthors = Jensen TS, Jacques LB, Ciccanti M, Long K, Eggleston L, Roche J |date = 3 August 2009 |publisher = Centers for Medicare and Medicaid Services |access-date = 14 April 2018 |url-status = live |archive-url = https://web.archive.org/web/20180414233940/https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=224&ver=15 |archive-date = 14 April 2018 }}</ref> A 2014 [[meta-analysis]] showed that using genotype-based dosing did not confer benefit in terms of time within therapeutic range, excessive anticoagulation (as defined by INR greater than 4), or a reduction in either major bleeding or thromboembolic events.<ref name=Stergiopoulos>{{cite journal | vauthors = Stergiopoulos K, Brown DL | title = Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials | journal = JAMA Internal Medicine | volume = 174 | issue = 8 | pages = 1330–1338 | date = August 2014 | pmid = 24935087 | doi = 10.1001/jamainternmed.2014.2368 | doi-access =  | title-link=doi }}</ref>

== History ==
In the early 1920s, an outbreak of a previously unrecognized cattle disease occurred in the [[northern United States]] and Canada. Cattle were [[haemorrhaging]] after minor procedures, and on some occasions spontaneously.<ref name="Distillations"/> For example, 21 of 22 cows died after dehorning and 12 of 25 bulls died after [[castration]], all by bleeding to death.<ref name="Laurence 1973 23.4-23.5">{{cite book |title = Clinical Pharmacology |vauthors = Laurence DR, Kneebone P |year = 1973 |publisher = Churchill Livingstone |location = Edinburgh, London and New York |pages = 23.4–23.5 |isbn = 978-0-443-04990-3 |url = https://archive.org/details/clinicalpharmaco0000laur |url-access = registration }}</ref>

In 1921, [[Frank Schofield]], a Canadian [[veterinary]] [[pathologist]], determined that the cattle were ingesting moldy [[silage]] made from [[Melilotus|sweet clover]], and that this was functioning as a potent anticoagulant.<ref name="Distillations"/> Only spoiled hay made from sweet clover (grown in northern states of the US and in Canada since the turn of the century) produced the disease.<ref>{{cite journal |author = Schofield FW |title = Damaged sweet clover; the cause of a new disease in cattle simulating haemorrhagic septicemia and blackleg |journal = J Am Vet Med Assoc |year = 1924 |volume = 64 |pages = 553–6 }}</ref> Schofield separated good clover stalks and damaged clover stalks from the same hay mow, and fed each to a different rabbit. The rabbit that had ingested the good stalks remained well, but the rabbit that had ingested the damaged stalks died from a haemorrhagic illness. A duplicate experiment with a different sample of clover hay produced the same result.<ref name="Laurence 1973 23.4-23.5" /> In 1929, [[North Dakota]] veterinarian Lee M. Roderick demonstrated that the condition was due to a lack of functioning [[prothrombin]].<ref>{{cite journal |author = Roderick LM |year = 1931 |title = A problem in the coagulation of the blood; "sweet clover disease of the cattle" |url = https://archive.org/details/sim_american-journal-of-physiology_1931-02-01_96_2/page/412 |journal = Am J Physiol |volume = 96 |issue = 2 |pages = 413–425 |doi = 10.1152/ajplegacy.1931.96.2.413 }}</ref>

The identity of the anticoagulant substance in spoiled sweet clover remained a mystery until 1940. In 1933, [[Karl Paul Link]] and his laboratory of chemists working at the [[University of Wisconsin–Madison|University of Wisconsin]] set out to isolate and characterize the haemorrhagic agent from the spoiled hay.<ref name="Distillations"/> Five years were needed before Link's student Harold A. Campbell recovered 6&nbsp;mg of crystalline anticoagulant. Next, Mark A. Stahmann, another of Link's students, took over the project and initiated a large-scale extraction, isolating 1.8 g of recrystallized anticoagulant in about 4 months. This was enough material for Stahmann and Charles F. Huebner to check their results against Campbell's and to thoroughly characterize the compound. Through degradation experiments, they established that the anticoagulant was 3,3'-methylenebis-(4-hydroxycoumarin), which they later named [[dicoumarol]]. They confirmed their results by synthesizing dicoumarol and proving in 1940 that it was identical to the naturally occurring agent.<ref>{{cite journal |vauthors = Stahmann MA, Huebner CF, Link KP |date = 1 April 1941 |title = Studies on the hemorrhagic sweet clover disease. V. Identification and synthesis of the hemorrhagic agent |journal = J Biol Chem |volume = 138 |pages = 513–27 |issue = 2 |doi = 10.1016/S0021-9258(18)51377-6 |doi-access = free | title-link = doi }}</ref>

Dicoumarol was a product of the plant molecule [[coumarin]] (not to be confused with Coumadin, a later tradename for warfarin). Coumarin is now known to be present in many plants, and produces the notably sweet smell of [[Smell of freshly cut grass|freshly cut grass]] or hay and plants such as [[Hierochloe odorata|sweet grass]]; in fact, the plant's high content of coumarin is responsible for the original common name of "sweet clover", which is named for its sweet smell, not its bitter taste.<ref name="Laurence 1973 23.4-23.5" /> They are present notably in [[Galium odoratum|woodruff]] (''Galium odoratum'', [[Rubiaceae]]), and at lower levels in [[licorice]], [[lavender]], and various other species. The name coumarin comes via the French ''coumarou'' from ''kumarú'', the [[Tupi language|Tupi]] name for the tree of the [[Dipteryx odorata|tonka bean]], which notably contains a high concentration of coumarin.<ref>{{cite web |title=Warfarin, Molecule of the Month for February 2011, by John Maher |url=https://www.chm.bris.ac.uk/motm/warfarin/ |access-date=20 December 2023 |website=www.chm.bris.ac.uk |archive-date=27 September 2023 |archive-url=https://web.archive.org/web/20230927151716/https://www.chm.bris.ac.uk/motm/warfarin/ |url-status=live }}</ref> However, coumarins themselves do not influence clotting or warfarin-like action. Coumarins must first be metabolized by various fungi into compounds such as [[4-hydroxycoumarin]], then further (in the presence of naturally occurring [[formaldehyde]]) into dicoumarol, to have any anticoagulant properties.

Over the next few years, numerous similar chemicals (specifically 4-hydroxycoumarins with a large [[aromatic]] substituent at the 3 position) were found to have the same anticoagulant properties. The first drug in the class to be widely commercialized was dicoumarol itself, patented in 1941 and later used as a [[pharmaceutical]]. Karl Link continued working on developing more potent coumarin-based anticoagulants for use as [[rodenticide|rodent poisons]], resulting in warfarin in 1948. The name "warfarin" stems from the acronym WARF, for [[Wisconsin Alumni Research Foundation]], with the ending "-arin" indicating its link with coumarin. Warfarin was first registered for use as a [[rodenticide]] in the US in 1948, and was immediately popular. Although warfarin was developed by Link, the Wisconsin Alumni Research Foundation financially supported the research and was assigned the patent.<ref name="pmid13619027">{{cite journal | vauthors = Link KP | title = The discovery of dicumarol and its sequels | journal = Circulation | volume = 19 | issue = 1 | pages = 97–107 | date = January 1959 | pmid = 13619027 | doi = 10.1161/01.CIR.19.1.97 | doi-access = free | title-link=doi }}</ref>

After an incident in 1951, in which an army inductee attempted suicide with multiple doses of warfarin in rodenticide, but recovered fully after presenting to a naval hospital and being treated with [[vitamin K]] (by then known as a specific [[antidote]]),<ref name="pmid13619027" /> studies began in the use of warfarin as a therapeutic anticoagulant.<ref name="Distillations">{{cite journal |vauthors=Rajagopalan R |title=A Study in Scarlet |url=https://www.sciencehistory.org/distillations/magazine/a-study-in-scarlet |journal=Distillations |date=2018 |volume=4 |issue=1 |pages=26–35 |access-date=27 June 2018 |archive-date=23 June 2019 |archive-url=https://web.archive.org/web/20190623094350/https://www.sciencehistory.org/distillations/magazine/a-study-in-scarlet |url-status=live }}</ref> It was found to be generally superior to dicoumarol, and in 1954, was approved for medical use in humans. An early recipient of warfarin was US President [[Dwight Eisenhower]], who was prescribed the drug after having a heart attack in 1955.<ref name="pmid13619027" />

The exact [[mechanism of action]] remained unknown until it was demonstrated, in 1978, that warfarin [[enzyme inhibitor|inhibits]] the enzyme [[vitamin K epoxide reductase]], and hence interferes with vitamin K metabolism.<ref name=Whitlon />

[[Lavrenty Beria]] and I. V. Khrustalyov are thought to have conspired to use warfarin to poison Soviet leader [[Joseph Stalin]]. Warfarin is tasteless and colourless, and produces symptoms similar to those that Stalin exhibited.<ref>{{cite book | vauthors = Naumov VP, Brent J |title = Stalin's last crime: the plot against the Jewish doctors, 1948–1953 |publisher = HarperCollins |location = London |year = 2003 |isbn = 978-0-06-019524-3 }}</ref>{{When|date=August 2025|reason=When were these symptoms exhibited?}}

===Occupational safety===
Warfarin used for pest control is a hazardous substance harmful to health. People can be exposed to warfarin in the workplace by breathing it in, swallowing it, skin absorption, and eye contact. The [[Occupational Safety and Health Administration]] has set the legal limit ([[permissible exposure limit]]) for warfarin exposure in the workplace as 0.1&nbsp;mg/m<sup>3</sup> over an 8-hour workday. The [[National Institute for Occupational Safety and Health]] has set a [[recommended exposure limit]] of 0.1&nbsp;mg/m<sup>3</sup> over an 8-hour workday. At levels of 100&nbsp;mg/m<sup>3</sup>, warfarin is [[IDLH|immediately dangerous to life and health]].<ref>{{cite web |title = CDC – NIOSH Pocket Guide to Chemical Hazards – Warfarin |url = https://www.cdc.gov/niosh/npg/npgd0665.html |website = www.cdc.gov |access-date = 27 November 2015 |url-status = live |archive-url = https://web.archive.org/web/20151208093728/http://www.cdc.gov/niosh/npg/npgd0665.html |archive-date = 8 December 2015 }}</ref>

It is classified as an [[List of extremely hazardous substances|extremely hazardous substance]] in the United States as defined in Section 302 of the U.S. [[Emergency Planning and Community Right-to-Know Act]] (42 U.S.C. 11002), and is subject to strict reporting requirements by facilities which produce, store, or use it in significant quantities.<ref name="gov-right-know">{{cite web |publisher = [[United States Government Publishing Office|Government Printing Office]] |title = 40 C.F.R.: Appendix A to Part 355—The List of Extremely Hazardous Substances and Their Threshold Planning Quantities |url = https://www.ecfr.gov/current/title-40/chapter-I/subchapter-J/part-355/appendix-Appendix%20A%20to%20Part%20355 |edition = 21 August 2023 |access-date = 22 August 2023 |archive-date = 9 January 2023 |archive-url = https://web.archive.org/web/20230109114558/https://www.ecfr.gov/current/title-40/chapter-I/subchapter-J/part-355/appendix-Appendix%20A%20to%20Part%20355 |url-status = live }}</ref>

== Society and culture ==
The name "warfarin" is derived from the acronym for "Wisconsin Alumni Research Foundation", plus "-arin", indicating its link with coumarin. Warfarin is a derivative of dicoumarol, an anticoagulant originally discovered in spoiled sweet clover. Dicoumarol, in turn, is from coumarin, a sweet-smelling but coagulation-inactive chemical found in "sweet" clover and [[Dipteryx odorata|tonka beans]] (also known as ''cumaru'' from which coumarin's name derives).

=== Brand names ===
Warfarin as a drug is marketed under many brand and generic names, including Aldocumar, Anasmol, Anticoag, Befarin, Cavamed, Cicoxil, Circuvit, Cofarin, Coumadin, Coumadine, Cumar, Farin, Foley, Haemofarin, Jantoven, Kovar, Lawarin, Maforan, Marevan, Marfarin, Marivanil, Martefarin, Morfarin, Orfarin, Panwarfin, Scheme, Simarc, Varfarin, Varfarins, Varfine, Waran, Warcok, Warf, Warfareks, Warfarin, Warfarina, Warfarine, Warfarinum, Warfen, Warfin, Warik, Warin, Warlin, and Zyfarin.<ref name=brands>{{cite web |title = Warfarin international brands |url = https://www.drugs.com/international/warfarin.html |publisher = Drugs.com |url-status = live|archive-url = https://web.archive.org/web/20170405172058/https://www.drugs.com/international/warfarin.html|archive-date=5 April 2017|date =12 February 2023}}</ref>

== Veterinary use ==
Warfarin is used as a [[Rodenticide#Anticoagulants|poison for rats]] and other pests.<ref name=poison>{{cite journal | vauthors = Lim GB | title = Milestone 2: Warfarin: from rat poison to clinical use | journal = Nature Reviews. Cardiology | date = December 2017 | pmid = 29238065 | doi = 10.1038/nrcardio.2017.172 | doi-access = free }}</ref><ref name=NZToxins/>

=== Pest control ===
Warfarin was introduced as a [[rodenticide]], only later finding medical uses; in both cases it was used as an anticoagulant.<ref name=poison/> The use of warfarin itself as a rat poison is declining, because many rat populations have developed resistance to it,<ref name="RRAC-anticoags"/> and poisons of considerably greater potency have become available. However, {{As of|2023|lc=y}} warfarin continued to be considered a valuable tool for rodent control which minimised risk to other species.<ref>{{cite web| title=Warfarin - A valuable tool for successful rodent control whilst minimising risk to non-target species| publisher=National Pest Technicians Association| date=21 October 2019| url=https://www.npta.org.uk/warfarin-a-valuable-tool-for-successful-rodent-control-whilst-minimising-risk-to-non-target-species/| access-date=18 February 2023| archive-date=17 February 2023| archive-url=https://web.archive.org/web/20230217044318/https://www.npta.org.uk/warfarin-a-valuable-tool-for-successful-rodent-control-whilst-minimising-risk-to-non-target-species/| url-status=live}}</ref>

====Rodents====
{{Main|4-hydroxycoumarins}}
[[File:Rattenvergifwaarschuwing edit.JPG|thumb|Warning label on a tube of rat poison laid on a dike of the [[Scheldt]] River in [[Steendorp, Belgium]]: The tube contains [[bromadiolone]], a second-generation ("super-warfarin") anticoagulant.]]

Coumarins (4-hydroxycoumarin derivatives) are used as [[rodenticide]]s for controlling [[rat]]s and [[mouse|mice]] in residential, industrial, and agricultural areas. Warfarin is both odorless and tasteless, and is effective when mixed with food [[bait (luring substance)|bait]], because the [[rodent]]s will return to the bait and continue to feed over a period of days until a lethal dose is accumulated (considered to be 1 mg/kg/day over about six days). It may also be mixed with [[talc]] and used as a tracking powder, which accumulates on the animal's skin and fur, and is subsequently consumed during grooming. The {{LD50}} for warfarin is 50–100{{nbsp}}mg/kg for a single dose, after 5–7 days.<ref name="RRAC-anticoags">{{cite web |url=http://croplife.org/wp-content/uploads/2015/10/Rodenticide-Resistance-Strategy_Sept2015v3.pdf |publisher=[[CropLife]] |website=[[RRAC]] |vauthors=Endepols S, Buckle A, Eason C, Pelz HJ, Meyer A, Berny P, Baert K, Prescott C |place=[[Brussels]] |date=September 2015 |pages=1–29 |title=RRAC guidelines on Anticoagulant Rodenticide Resistance Management |access-date=23 October 2021 |archive-date=4 November 2021 |archive-url=https://web.archive.org/web/20211104132536/https://croplife.org/wp-content/uploads/2015/10/Rodenticide-Resistance-Strategy_Sept2015v3.pdf |url-status=live }}</ref> {{LD50}} 1{{nbsp}}mg/kg for repeated daily doses for 5 days, after 5–8 days.<ref name="RRAC-anticoags" /> The [[IDLH]] value is 100&nbsp;mg/m<sup>3</sup> (warfarin; various species).<ref>{{cite web |url = https://www.cdc.gov/niosh/idlh/81812.html |title = Documentation for Immediately Dangerous To Life or Health Concentrations (IDLHs): Warfarin |author = United States [[Occupational Safety and Health Administration]] (OSHA) |date = 16 August 1996 |publisher = [[Centers for Disease Control and Prevention]] |access-date = 7 July 2008 |url-status = live |archive-url = https://web.archive.org/web/20080726031247/http://www.cdc.gov/niosh/idlh/81812.html |archive-date = 26 July 2008 }}</ref>

Resistance to warfarin as a poison has developed in many rat populations due to an [[autosomal]] [[dominant (genetics)|dominant]] on chromosome 1 in [[brown rat]]s.<ref name="RRAC-anticoags" /> This has [[convergent evolution|arisen independently and become fixed]] several times around the world.<ref name="RRAC-anticoags" /> Other 4-hydroxycoumarins used as rodenticides include [[coumatetralyl]] and [[brodifacoum]], which is sometimes referred to as "super-warfarin", because it is more potent, longer-acting, and effective even in rat and mouse populations that are resistant to warfarin. Unlike warfarin, which is readily excreted, newer anticoagulant poisons also [[bioaccumulation|accumulate]] in the [[liver]] and [[kidney]]s after ingestion.<ref name=NZToxins>{{cite book |title = Vertebrate pesticide toxicology manual (poisons) |vauthors = Eason CT, Wickstrom M |year = 2001 |publisher = [[Department of Conservation (New Zealand)|New Zealand Department of Conservation]] |chapter = 2. Anticoagulant poisons |chapter-url=http://www.doc.govt.nz/upload/documents/science-and-technical/docts23b.pdf |pages = 41–74 |isbn = 978-0-478-22035-3 |url-status = live |archive-url = https://web.archive.org/web/20081017022833/http://www.doc.govt.nz/upload/documents/science-and-technical/docts23b.pdf |archive-date = 17 October 2008 }}</ref> However, such rodenticides may also accumulate in [[birds of prey]] and other animals that eat the poisoned rodents or baits.<ref>{{cite news |title = Killing rats is killing birds |vauthors = Lovett RA |date = 14 November 2012 |access-date = 5 April 2015 |url = http://www.nature.com/news/killing-rats-is-killing-birds-1.11824 |journal = [[Nature (journal)|Nature]] |doi = 10.1038/nature.2012.11824 |url-status = live |archive-url = https://web.archive.org/web/20150426133605/http://www.nature.com/news/killing-rats-is-killing-birds-1.11824 |archive-date = 26 April 2015 }}</ref>

==== Vampire bats ====
Warfarin is used to cull populations of [[vampire bat]]s, in which [[rabies]] is often prevalent, in areas where [[human–wildlife conflict]] is a concern.<ref name="Johnson 2014">{{cite journal | vauthors = Johnson N, Aréchiga-Ceballos N, Aguilar-Setien A | title = Vampire bat rabies: ecology, epidemiology and control | journal = Viruses | volume = 6 | issue = 5 | pages = 1911–1928 | date = April 2014 | pmid = 24784570 | pmc = 4036541 | doi = 10.3390/v6051911 | doi-access = free | title-link=doi }}</ref> Vampire bats are captured with [[mist net]]s and coated with a combination of [[petroleum jelly]] and warfarin. The bat returns to its roost and other members of the roost become poisoned as well by ingesting the warfarin after [[reciprocal grooming]].<ref name="Johnson 2014" /> Suspected vampire bat roosts may also be coated in the warfarin solution, though this kills other bat species and remains in the environment for years.<ref name="Johnson 2014" /> The efficacy of killing vampire bats to reduce rabies transmission is questionable; a study in [[Peru]] showed that culling programs did not lead to lower transmission rates of [[rabies]] to livestock and humans.<ref name="Streicker 2012">{{cite journal | vauthors = Streicker DG, Recuenco S, Valderrama W, Gomez Benavides J, Vargas I, Pacheco V, Condori Condori RE, Montgomery J, Rupprecht CE, Rohani P, Altizer S | title = Ecological and anthropogenic drivers of rabies exposure in vampire bats: implications for transmission and control | journal = Proceedings. Biological Sciences | volume = 279 | issue = 1742 | pages = 3384–3392 | date = September 2012 | pmid = 22696521 | pmc = 3396893 | doi = 10.1098/rspb.2012.0538 }}</ref>

=== Brand names ===
Warfarin as a pest control poison is marketed under many brand and generic names, including Cov-R-Tox, Co-Rax, d-Con, Dethmor, Killgerm Sewercide, Mar-Fin, Rattunal, Rax, Rodex, Rodex Blox, Rosex, Sakarat, Sewarin, Solfarin, Sorex Warfarin, Tox-Hid, Warf, warfarin, and Warfarat. Warfarin is called coumafene in France, zoocoumarin in the Netherlands and Russia, and coumarin in Japan.<ref name=brands2>{{cite web | title=Pesticide Information Profiles: WARFARIN | website=EXTOXNET Extension Toxicology Network | url=http://extoxnet.orst.edu/pips/warfarin.htm | date=September 1995 | access-date=18 February 2023 | archive-date=10 June 2023 | archive-url=https://web.archive.org/web/20230610174038/http://extoxnet.orst.edu/pips/warfarin.htm | url-status=live }}</ref><ref name=brands3>{{cite web | title=Rat poison product list | website=The Barn Owl Trust | date=22 September 2021 | url=https://www.barnowltrust.org.uk/hazards-solutions/rodenticides/rat-poison-product-list/ | access-date=18 February 2023 | archive-date=18 February 2023 | archive-url=https://web.archive.org/web/20230218154554/https://www.barnowltrust.org.uk/hazards-solutions/rodenticides/rat-poison-product-list/ | url-status=live }}</ref>

== References ==
{{Reflist}}

== Further reading ==
* {{cite book | title=Medical Genetics Summaries | chapter=Warfarin Therapy and VKORC1 and CYP Genotype | chapter-url=https://www.ncbi.nlm.nih.gov/books/NBK84174/ | veditors=Pratt VM, McLeod HL, Rubinstein WS, Scott SA, Dean LC, Kattman BL, Malheiro AJ | display-editors=6 | publisher=[[National Center for Biotechnology Information]] (NCBI) | year=2012 | pmid=28520347 | id=Bookshelf ID: NBK84174 | vauthors=Dean L | url=https://www.ncbi.nlm.nih.gov/books/NBK61999/ }}

== External links ==
* {{PPDB|681}}
{{clear}}

{{Antithrombotics}}
{{rodenticides}}
{{Portal bar | Medicine}}
{{Authority control}}

[[Category:4-Hydroxycoumarins]]
[[Category:Anticoagulant rodenticides]]
[[Category:Coumarin drugs]]
[[Category:Teratogens]]
[[Category:World Health Organization essential medicines]]
[[Category:Wikipedia medicine articles ready to translate]]